A Phase I, Open Label, 2 Part Study to Determine the Pharmacokinetics of Olaparib 300 mg bd Administered as Monotherapy and Olaparib 100 mg bd as Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours

Trial Profile

A Phase I, Open Label, 2 Part Study to Determine the Pharmacokinetics of Olaparib 300 mg bd Administered as Monotherapy and Olaparib 100 mg bd as Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Olaparib (Primary) ; Paclitaxel
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 20 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
    • 24 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top